NMPA Market Access

Invest in knowledge, train your staff


NMPA Basic training

Since the Chinese Medical Device Regulation overhaul in 2014, the market has witnessed countless updates in its regulatory rules, technical guidance, and standards. Manufacturers which want to sell their medical devices and in vitro diagnostics to the Chinese market need to have a device registration with the National Medical Products Administration (NMPA).

There has been a recent governmental reorganization where the formal regulatory body, CFDA (China Food & Drug Administration), integrated into the new CNDA (China National Drug Administration). This seems to herald more changes into the current regulatory framework. 

New requirements on clinical evidence, China Agent, overseas inspections etc. bring forth both opportunities and challenges for the foreign medical device manufacturers. 

The training

This training will give an overview of the Chinese medical device regulatory landscape and provide details which are essential for successful product registration in China. New regulatory requirements such as classification, China Agent, vigilance, clinical evaluation and clinical trial etc. will be included in the training as well. 





Program overview

  • Introduction to Chinese regulatory & regulations overview
  • Timeline, planning, and budgeting for NMPA (former CFDA) registration;
  • Classification;
  • Registration routes;
  • Submission file;
  • Clinical evaluation and clinical trial;
  • In-China lab testing;
  • China Agent;
  • Vigilance;
  • Dos and Don’ts with NMPA (former CFDA);
  • Questions & Answers;
  • Evaluation of the Course and closing.

During the course case studies are used to practice the learnings.

Learning Objectives

  • Understand the current regulatory framework in China;
  • Learn what is needed for typical planning and budgeting for product registration in China;
  • Learn to classify your medical device and select an appropriate market access route;
  • Learn the high-level submission file requirements;
  • Learn the requirements of clinical evidence;
  • Understand the roles and responsibilities of different stakeholders (e.g. China Agent, NMPA, distributor etc.) in relation to the foreign manufacturer during and after the registration.



Who should attend?

 A foreign manufacturer who had no or limited NMPA (former CFDA) experience.



We offer open enrolment, on-location, train-the-trainer formats.

Please contact us to schedule in-house training, which is also recommended for training multiple colleagues or teams at the same time.